Quince Therapeutics, Inc. Net Income Loss

Quick Answer

Quince Therapeutics, Inc. reported Net Income Loss of -$56.83 million for the year ending 2024.

  • Quince Therapeutics, Inc. showed a decrease of -81.1% in Net Income Loss from 2023 to 2024.
  • This data is from Quince Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2025.
  • XBRL data for this metric is available from 2018 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 7 years of available data (2018 to 2024), Quince Therapeutics, Inc.'s Net Income Loss has declined by 355.5%.
  • Historical annual values: Fiscal year 2024: -$56.83 million | Fiscal year 2023: -$31.39 million | Fiscal year 2022: -$51.66 million | Fiscal year 2021: -$89.95 million | Fiscal year 2020: -$76.85 million | Fiscal year 2019: -$36.98 million | Fiscal year 2018: -$12.48 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: